P-6 SOFOSBUVIR CONTAINING REGIMENS ARE SAFE AND EFFECTIVE IN ADOLESCENTS WITH CHRONIC HEPATITIS C INFECTION

• Published in: Annals of hepatology 2021-09, Vol.24, p.100372, Article 100372
• Main Authors: Wirth, Stefan, Gonzalez-Peralta, Regino, Rosenthal, Philip, Hardikar, Winita, Wen, Jessica, Jonas, Maureen M., Mittal, Naveen, Whitworth, Mary, Arnon, Ronen, Lin, Chuan-Hao, Lobzin, Yury, Romero, Rene, Chulanov, Vladimir, Subbarao, Girish, Teckman, Jeffrey, Morozov, Vyacheslav, Bassetti, Eric, Kersey, Kathryn, Massetto, Benedetta, Zhu, Yanni, German, Polina, Brainard, Diana M., Bansal, Sanjay, Murray, Karen F., Schwarz, Kathleen, Balistreri, William
• Format: Article
• Language: English
• ISSN: 1665-2681; 2659-5982
• DOI: 10.1016/j.aohep.2021.100372

HCV-specific DAAs have transformed treatment of chronic HCV, but few studies have evaluated these therapies in children. Patients aged 12–17 years old with chronic GT1 HCV were enrolled into an open-label study to receive 12 weeks of LDV/SOF 90 mg/400 mg once daily, and those with HCV GT2 or GT3 to receive SOF (400 mg once daily) + RBV (15 mg/kg/day) for 12 (GT2) or 24 weeks (GT3), respectively. Primary efficacy endpoint was SVR12. Safety was assessed by adverse events and clinical/laboratory data. Pharmacokinetic (PK) sampling was conducted to confirm the appropriateness of the doses. 150 adolescents (100 GT1, 13 GT2 and 37 GT3) were enrolled and treated. The majority were female (56%), white (90%), treatment naive (81%), and vertically infected (80%). The mean age was 15 years (range 12–17). LDV, SOF and GS-331007 (primary metabolite) exposures were within the range of adult exposures observed in the SOF and LDV/SOF phase 2/3 studies. The SVR12 rate was 98% in GT1, 100% in GT2 and 97% in GT3; all 3 patients who were considered not to have achieved SVR12 were lost to follow-up. No adverse event (AE) leading to study drug discontinuation or serious AEs have been reported. In adolescents, LDV/SOF for 12 weeks and SOF + RBV for 12 or 24 weeks, resulted in a SVR12 rate of 97–100% with no virologic failures. These regimens were well tolerated, demonstrating their potential as an important treatment option for children with HCV infection.